Industry Research Reports: Market Research Report

Showing posts with label Market Research Report. Show all posts

Friday 18 December 2015

Apceth GmbH & Co. KG - Product Pipeline Review Market Segmentation and Forecast 2015 - Acute Market Reports

Summary

'Apceth GmbH & Co. KG. - Product Pipeline Review - 2015', provides an overview of the Apceth GmbH & Co. KG.'s pharmaceutical research and development focus.

View Full Report: http://www.acutemarketreports.com/report/apceth-gmbh-co-kg-product-pipeline-review-2015

This report provides comprehensive information on the current therapeutic developmental pipeline of Apceth GmbH & Co. KG.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Download Full Report With TOC: http://www.acutemarketreports.com/request-free-sample/49436

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Apceth GmbH & Co. KG. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Apceth GmbH & Co. KG.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Apceth GmbH & Co. KG.'s pipeline products

View all Reports of this Category @: http://www.acutemarketreports.com/category/healthcare-market

Reasons to buy

- Evaluate Apceth GmbH & Co. KG.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Apceth GmbH & Co. KG. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Apceth GmbH & Co. KG.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Apceth GmbH & Co. KG. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Apceth GmbH & Co. KG.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Apceth GmbH & Co. KG. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

About Us:

Acute Market Reports is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements. We provide online reports from over 100 best publishers and upgrade our collection regularly to offer you direct online access to the world’s most comprehensive and recent database with expert perceptions on worldwide industries, products, establishments and trends. Our database consists of 200,000+ market research reports with detailed & minute market research.

Acute Market Reports

Office No 101, 1st Floor,

Aditi Mall, Baner,

Pune, MH, 411045

India

Toll Free(US/CANADA): +1-855-455-8662

Email: sales@acutemarketreports.com

Blog: http://industry-research-reports.blogspot.com/

Website: http://www.acutemarketreports.com/

BiOrion Technologies B.V. - Product Pipeline Review Market Overview 2010 - Acute Market Reports

Summary

'BiOrion Technologies B.V. - Product Pipeline Review - 2015', provides an overview of the BiOrion Technologies B.V.'s pharmaceutical research and development focus.

View Full Report: http://www.acutemarketreports.com/report/biorion-technologies-bv-product-pipeline-review-2015

This report provides comprehensive information on the current therapeutic developmental pipeline of BiOrion Technologies B.V.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Download Full Report With TOC: http://www.acutemarketreports.com/request-free-sample/49435

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of BiOrion Technologies B.V. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of BiOrion Technologies B.V.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the BiOrion Technologies B.V.'s pipeline products

View all Reports of this Category @: http://www.acutemarketreports.com/category/healthcare-market

Reasons to buy

- Evaluate BiOrion Technologies B.V.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of BiOrion Technologies B.V. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the BiOrion Technologies B.V.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of BiOrion Technologies B.V. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of BiOrion Technologies B.V.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of BiOrion Technologies B.V. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

About Us:

Acute Market Reports

Office No 101, 1st Floor,

Aditi Mall, Baner,

Pune, MH, 411045

India

Toll Free(US/CANADA): +1-855-455-8662

Email: sales@acutemarketreports.com

Blog: http://industry-research-reports.blogspot.com/

Website: http://www.acutemarketreports.com/

Thursday 17 December 2015

Ambryx Biotechnology, Inc. - Product Pipeline Review Market Edition 2015 - Acute Market Reports

Summary

Global Markets Direct's, 'Ambryx Biotechnology, Inc. - Product Pipeline Review - 2015', provides an overview of the Ambryx Biotechnology, Inc.'s pharmaceutical research and development focus.

View Full Report: http://www.acutemarketreports.com/report/ambryx-biotechnology-inc-product-pipeline-review-2015

This report provides comprehensive information on the current therapeutic developmental pipeline of Ambryx Biotechnology, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Download Full Report With TOC: http://www.acutemarketreports.com/request-free-sample/49434

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Ambryx Biotechnology, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Ambryx Biotechnology, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Ambryx Biotechnology, Inc.'s pipeline products

View all Reports of this Category @: http://www.acutemarketreports.com/category/healthcare-market

Reasons to buy

- Evaluate Ambryx Biotechnology, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Ambryx Biotechnology, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Ambryx Biotechnology, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Ambryx Biotechnology, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ambryx Biotechnology, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Ambryx Biotechnology, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

About Us:

Acute Market Reports

Office No 101, 1st Floor,

Aditi Mall, Baner,

Pune, MH, 411045

India

Toll Free(US/CANADA): +1-855-455-8662

Email: sales@acutemarketreports.com

Blog: http://industry-research-reports.blogspot.com/

Website: http://www.acutemarketreports.com/

Global Versatile Innovation in Oncology Market Segmentation and Forecast 2021 - Acute Market Reports

Summary

The oncology therapy area comprises a large and diverse range of indications, encompassing virtually all sites and tissues in the human body. These indications are the leading cause of death in economically developed countries and the second-leading cause of death in developing countries and present a major global health burden. Across the pharmaceutical industry as a whole, the oncology pipeline is far larger than any other therapy area, with 6,484 products in active development across all oncology indications, and 2,084 first-in-class products in development across all stages.

View Full Report: http://www.acutemarketreports.com/report/frontier-pharma-versatile-innovation-in-oncology-identifying-and-commercializing-versatile-first-in-class-innovation

Due to a degree of crossover between oncology indications in terms of their underlying pathophysiology, it is not uncommon for products being developed for this therapy area to have developmental programs testing them across multiple indications. Some 473 first-in-class pipeline products are in concurrent development for two or more of the top 20 cancer sites ranked by incidence. The most promising versatile first-in-class molecular targets predominantly consist of receptor tyrosine kinases and their downstream signal transduction kinases, although a number of other cancer-related processes such as DNA repair, cancer immunosurveillance and apoptotic pathways are also targeted.

Scope

- With 6,484 products in active development across all oncology indications, this is the largest therapy area pipeline by a considerable margin.

- What factors are driving this high level of R&D activity?

- Which indications have the highest concentration of pipeline products?

- Although the unmet need varies between and within indications, this need is primarily for improved overall survival rates in patients, particularly those at the late stage of the disease.

- Which first-in-class molecular targets appear able to best address the key unmet needs within oncology?

- The variation in molecule type has shifted away from small molecules, the dominance of which has decreased from 94% across marketed products to 49% across the pipeline.

- What are the dynamics of the remaining 51% of the pipeline?

Download Full Report With TOC: http://www.acutemarketreports.com/request-free-sample/48570

- How does this reflect the need for novel targeted therapies?

- There has been a significant shift towards inhibitors of receptor tyrosine kinases, their ligands and signal transduction proteins, as well as drugs targeted against cancer antigens.

- What is the scientific rationale behind these targets? Across which indications are they being developed?

- How successful have drugs against these targets been?

- A number of versatile first-in-class targets appear to be particularly promising, including HER3, FGFR3, telomerase reverse transcriptase, and others.

- Why are these targets considered to be particularly promising?

- Why are these targets being developed across such a wide range of indications?

View all Reports of this Category @: http://www.acutemarketreports.com/category/healthcare-market

Reasons to buy

- Understand the current clinical and commercial landscape by considering disease pathogenesis, diagnosis, prognosis, and the treatment options across the key oncology indications

- Acquire a detailed understanding of the 20 most common oncology indications by incidence, pinpointing the unmet needs for each indication

- Assess the market for oncology in terms of the molecular targets that are approved across multiple indications and the predominant molecule types and targets

- Analyze the oncology pipeline and stratify by stage of development, molecule type, molecular target, and first-in-class status

- Understand the level of versatility across the pipeline and within each molecular target. Assess the pipeline activity of each versatile first-in-class product and the indications that they are in development for

- Analyze the therapeutic potential and developmental footprint of versatile first-in-class targets and understand which are the most promising. Understand which targets are being developed in each indication, for how many pipeline products, and how well they align with the underlying pathophysiology of cancer

- Identify commercial opportunities in the oncology deals landscape by analyzing trends in licensing and co-development deals for versatile first-in-class products

- Identify versatile first-in-class pipeline products that have not been previously involved in licensing or co-development deals and are thus more likely to be available for in-licensing or co-development

About Us:

Acute Market Reports

Office No 101, 1st Floor,

Aditi Mall, Baner,

Pune, MH, 411045

India

Toll Free(US/CANADA): +1-855-455-8662

Email: sales@acutemarketreports.com

Blog: http://industry-research-reports.blogspot.com/

Website: Acute Market Reports

Multiple Myeloma Therapeutics in Major Developed Market Overview 2010 - Acute Market Reports

Summary

Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. It is the second-most frequently diagnosed hematological malignancy, with an annual prevalence in the US of about 45,000. The disease is considered incurable, although the past decade has seen significant improvements in therapy, driven by a greater understanding of pathophysiology. Many of the leading drugs in the market were approved over the past 10–15 years, and have improved median survival rates by about 50%.

View Full Report: http://www.acutemarketreports.com/report/multiple-myeloma-therapeutics-in-major-developed-markets-to-2021-growth-driven-by-rising-prevalence-continued-success-of-revlimid-and-emerging-supplementary-treatments

The MM pipeline contains 267 products in active development, encompassing a range of molecule types and therapeutic targets. The innovation that has characterized the market over recent years is also clearly present in the current pipeline, with a strong presence of novel, targeted products.

Scope

- The MM market landscape has undergone significant change over the past two decades.

- Which classes of drug have emerged to dominate the market?

- What survival benefits have these drugs produced?

- How do the leading marketed therapies compare clinically?

- The pipeline contains a range of molecule types and molecular targets not present in the current market, including a strong focus on therapies targeting common oncogenic pathways, such as the Phosphoinositide 3-Kinase/Protein Kinase B (PI3K/Akt) pathway.

Download Full Report With TOC: http://www.acutemarketreports.com/request-free-sample/48571

- Which molecular targets appear most frequently in the pipeline?

- How will the new therapies be positioned in the treatment of MM?

- How have selected late-stage pipeline therapies performed in clinical trials?

- MM clinical trials have an overall attrition rate of 78%.

- What are the failure rates for individual Phases of clinical development?

- How do MM clinical trial characteristics, including failure rate, duration, and size compare against oncology and industry averages?

- The MM market is forecast to rise from a value of $7.3 billion in 2014 to $8.9 billion in 2021, at a CAGR of 2.9% across the eight major markets assessed.

- How much of a role will disease prevalence and new product approvals play in market growth?

- Will generic competition have a significant impact on the market over the forecast period?

- There have been 39 licensing deals and 22 co-development deals pertaining to MM products since 2006.

- Which territories show the most deal activity?

- What were the trends in deal completion by product stage of development?

- What were the conditions of the key licensing or co-development deals to take place in MM?

View all Reports of this Category @: http://www.acutemarketreports.com/category/pharmaceutical-market

Reasons to buy

- Understand the current clinical and commercial landscape through a comprehensive study of disease pathogenesis, diagnosis, prognosis, and the current treatment algorithm used in MM.

- Assess the safety and efficacy of current treatment options, with extensive product profiles on prominent marketed therapies and a heatmap directly comparing safety and efficacy data.

- Analyze the MM pipeline and stratify by stage of development, molecule type, and molecular target. The most promising late-stage therapies are profiled and assessed in terms of clinical performance and competitiveness, alongside a single-product forecast.

- Predict growth in market size in eight major markets, with in-depth market forecasting from 2014–2021. The forecasts will provide an understanding of how epidemiology trends, new drug entry, and patent expirations will influence market value.

- Identify commercial opportunities in the MM deals landscape by analyzing trends in licensing and co-development deals, and by profiling the most significant deals that have occurred in this indication in recent years.

About Us:

Acute Market Reports

Office No 101, 1st Floor,

Aditi Mall, Baner,

Pune, MH, 411045

India

Toll Free(US/CANADA): +1-855-455-8662

Email: sales@acutemarketreports.com

Blog: http://industry-research-reports.blogspot.com/

Website: Acute Market Reports

Wednesday 16 December 2015

Systemic Psoriasis Therapeutics in Asia Pacific Market Edition 2021 - Acute Market Reports

""Systemic Psoriasis Therapeutics in Asia-Pacific Markets to 2021 - Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth"", which provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis carried out by GBI Research’s team of industry experts.

View Full Report: http://www.acutemarketreports.com/report/systemic-psoriasis-therapeutics-in-asia-pacific-markets-to-2021-advent-of-novel-biologics-and-expanding-treatment-pool-to-drive-growth

In 2014, the value of the psoriasis therapeutics market in APAC amounted to an estimated $435m, and it is forecast to grow at a Compound Annual Growth Rate (CAGR) of 8.4% between 2014 and 2021 to reach $773m. The psoriasis treatment landscape is a particularly complex one. More than 80% of patients fall into the mild-or-moderate category, for which the first line of treatment is topical drugs, phototherapy, or a combination. In the case of severe patients, non-steroidal drugs such as methotrexate, cyclosporine, and acitretin are practiced as first-line treatment; however, they come with toxicity concerns and so cannot be prescribed for long durations. Biologics such as TNF inhibitors (adalimumab, etanercept, infliximab) and ustekinumab are largely prescribed as second-line therapy when none of the aforementioned options provide the desired results. However, during the forecast period, biologics are likely gain a significant market share due to healthcare plans in APAC and awareness regarding the effectiveness of biologics. Among the recently launched biologics, Cosentyx (secukinumab) from Novartis has shown better efficacy than Enbrel (etanercept), and is a novel molecule that targets Interluekin-17 (IL-7). Biocon India has launched Alzumab (itolizumab), which is a first-in-class novel molecule that targets CD6 protein. It is anticipated to be the leading biologic in India by the end of forecast period. Humira (adalimumab), Enbrel (etanercept), and Remicade (infliximab) are expected to lose their patent during the forecast period, but will be compensated for by biosimilar versions.

Download Full Report With TOC: http://www.acutemarketreports.com/request-free-sample/48572

Scope

The report analyzes treatment use patterns, market characterization, the pipeline, and key licensing and co-development deals for psoriasis in the APAC markets of China, India, Japan, and Australia.The report includes -

- A brief introduction to psoriasis, including pathophysiology, etiology, diagnosis, and treatment algorithms

- In-depth analysis of currently marketed drugs, including analysis of safety, efficacy, treatment patterns, and strengths/weaknesses, along with a heat map comparing them in terms of safety and efficacy

- A comprehensive review of the pipeline for psoriasis, including individual analysis of a number of late-stage pipeline drugs likely to enter the market during the forecast period; the pipeline is further analyzed on the basis of phase distribution, molecule type, program type, mechanism of action, and molecular target

- Additional in-depth analysis of pipeline drug clinical trials by phase, trial size, trial duration, and program failure rate for each molecule type

- Multi-scenario forecast data for the market to 2021, taking into account how it might be affected by the introduction of new drugs, the expiry of key patents on current drugs, and changes in disease epidemiology across the key developed markets

- Discussion of the drivers of and barriers to market growth

- In-depth analysis of all licensing and co-development deals that have occurred in the psoriasis market since 2006

View all Reports of this Category @: http://www.acutemarketreports.com/category/pharmaceutical-market

Reasons to buy

The report will enhance your decision-making capability by allowing you to -

- Understand the psoriasis pipeline and the factors that indicate that it is becoming more innovative

- Analyze detailed profiles for promising pipeline products and gain insights into how they are likely to compete in the market and who their main competitors will be

- Follow the trends in psoriasis clinical trial size and duration in relation to industry averages

- Assess the potential risk of future developmental programs for psoriasis therapeutics by mechanism of action using recorded clinical trial failure rates

- Analyze the potential growth patterns expected for the psoriasis market over the forecast period

- Identify the countries that are expected to contribute the most to this growth and devise a more effectively tailored country strategy through an understanding of key drivers and barriers

- Accelerate and strengthen your market position by identifying key companies for strategic partnerships

About Us:

Acute Market Reports

Office No 101, 1st Floor,

Aditi Mall, Baner,

Pune, MH, 411045

India

Toll Free(US/CANADA): +1-855-455-8662

Email: sales@acutemarketreports.com

Blog: http://industry-research-reports.blogspot.com/

Website: Acute Market Reports

Contract Research Organization Market Edition 2015 - Acute Market Reports

Contract Research Organization Market: Global Deals and Operational Strategies” discusses the deal making activity during the past five years and in-depth analysis of the key deals involving more than 40 public and privately held CROs. The operational strategies adopted by key players in the recent years have been listed. A heatmap analysis of the key companies was done based on their firm utilization and capital management. SWOT analysis and profiles are given for the key companies in the market.

View Full Report: http://www.acutemarketreports.com/report/contract-research-organization-market

Companies mentioned in the report are Quintiles, Covance, Parexel, Catalent, ICON, PRA Health, Charles River, INC Research, WuXi PharmaTech, CMIC Holdings, EPS Corporation, Recipharm, Novotech, Laboratory Corporation of America Holdings, Consort Medical, Meiji Seika, Eurofins Scientific, Simbec Research, Hangzhou Tigermed, MPI Research, Sun Pharma, Noble Life Sciences, Chiltern International, BioPharma, Carlina, Euprotech, Protagen, Assign, Aurigon, Celonic and PharmaLex, Cromos Pharma, Avillion, Pfizer, Sanofi, Harlan Labs, Almac Group, Jubilant Biosys

Scope

The scope of the report includes:

-Overview of key reasons behind outsourcing, outsourcing service models

-Examples of operational strategies
-Global deals analysis by type and value
-Major acquisitions and partnerships
-Regional analysis of North America, Europe, Asia-Pacific and Emerging markets
-Company benchmarking based on heatmap analysis
-Vendor positioning
-SWOT analysis and profiles of key players

Download Full Report With TOC: http://www.acutemarketreports.com/request-free-sample/35533

Reasons To Buy

The report will enhance your decision-making capability by allowing you to:

-Identify the top players in the CRO market, financial revenues and key services offered
-Analyze the key geographies that are lucrative markets for deal making, market-entry and market expansion strategies
-Analyze the trends in acquisitions, licensing and other type of deals and explore potential investment opportunities
-Understand the operational strategies of key players

Executive Summary
Introduction
Market Dynamics
Operating Models
Examples of Operational Strategies
Global Deal Analysis
Collaborations and Acquisitions
Major Acquisitions
Major Partnerships
Regional Analysis
North America
Deal Analysis
Service Delivery and Operational Strategies
View all Reports of this Category @: http://www.acutemarketreports.com/category/industry-profile-market

Partnerships
Revenue and Growth Leaders
Europe
Deal Analysis
Service Delivery and Operational Strategies
Partnerships
Revenue and Growth Leaders
Asia-Pacific
Deal Analysis
Service Delivery and Operational Strategies
Partnerships
Revenue and Growth Leaders
Emerging Markets
Market Assessment
Acquisitions
Firm Utilization
Firm Utilization and Capital Management
Company Benchmarking
Vendor Positioning
Profiles and SWOT Analysis

About Us:

Acute Market Reports

Office No 101, 1st Floor,

Aditi Mall, Baner,

Pune, MH, 411045

India

Toll Free(US/CANADA): +1-855-455-8662

Email: sales@acutemarketreports.com

Blog: http://industry-research-reports.blogspot.com/

Website: Acute Market Reports

Alcohol Addiction - Pipeline Review, H2 Market Size, Growth, Trends, Market Analysis and Forecast – By Acute Market Reports

This report provides comprehensive information on the therapeutic development for Alcohol Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alcohol Addiction and special features on late-stage and discontinued projects.

View Full Report: http://www.acutemarketreports.com/report/alcohol-addiction-pipeline-review-h2-2015

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Download Full Report With TOC: http://www.acutemarketreports.com/request-free-sample/48760

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Alcohol Addiction
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Alcohol Addiction and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Alcohol Addiction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Alcohol Addiction pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products

View all Reports of this Category @: http://www.acutemarketreports.com/category/biopharmaceutical-market

Reasons to Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Alcohol Addiction
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Alcohol Addiction pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

About Us:

Acute Market Reports

Office No 101, 1st Floor,

Aditi Mall, Baner,

Pune, MH, 411045

India

Toll Free(US/CANADA): +1-855-455-8662

Email: sales@acutemarketreports.com

Blog: http://industry-research-reports.blogspot.com/

Website: Acute Market Reports

Systemic Psoriasis Therapeutics in Asia Pacific Market Business Survey Report 2021 - Acute Market Reports

Acute Market Reports, the leading business intelligence provider, has released its latest research, ""Systemic Psoriasis Therapeutics in Asia-Pacific Markets to 2021 - Advent of Novel Biologics and Expanding Treatment Pool to Drive Growth"", which provides insights into psoriasis therapeutics in the Asia-Pacific (APAC) market. For the purposes of this report, APAC refers to the market in China, India, Japan, and Australia only. The report estimates the market size for 2014, along with forecasts until 2021. It also covers disease epidemiology, treatment algorithms, treatment use patterns, in-depth analysis of pipeline molecules, clinical trial failure rates, and analysis of recent deals. It is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis carried out by GBI Research’s team of industry experts.